Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is ...
Ad.IL-12 was administered in doses ranging from 2.5 × 10 10 to 3 × 10 12 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients ...
AZoNano on MSN
Ultrasound-Activated Nanobubbles Soften Tumors to Boost RNA Nanoparticle Immunotherapy
Ultrasound-mediated nanobubbles improve cancer therapy by softening tumors, enhancing lipid nanoparticle distribution, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results